---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-23-000011"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T12:54:29.961014+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q4 commercial revenue $4.4M, FY2022 $17.1M; guides FY2023 at least $22M

## Summary
- Q4 2022 commercial revenue $4.4M (vs $4.9M prior year); net loss $16.4M ($0.39 per share).
- Full year 2022 commercial revenue $17.1M (vs $21.6M prior year); net loss $60.8M ($1.43 per share).
- Recurring commercial revenue grew 28% in Q4 to $2.9M; full year recurring revenue $11.0M (+40% YoY).
- Placed 2 new systems in Q4, 9 in full year; cumulative 125 placed, 103 validated systems.
- FY2023 guidance: commercial revenue at least $22M, with at least 15 new system placements.

## SEC filing metadata
- accession: 0001380106-23-000011
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/rpid-20230303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-23-000011
- JSON: https://secwatch.observer/filing/0001380106-23-000011.json
- Plain text: https://secwatch.observer/filing/0001380106-23-000011.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $4.4 million, net income $16.4 million, EPS $0.39.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $4.4 million
  - Net income: $16.4 million
  - EPS: $0.39
  - Result: reported results
  source text: Total revenue for the fourth quarter of 2022 was $4.4 million, compared to $5.2 million in the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported the fiscal year ended December 31, 2022 results: revenue $17.1 million, net income $60.8 million, EPS $1.43.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $17.1 million
  - Net income: $60.8 million
  - EPS: $1.43
  - Result: reported results
  source text: Total revenue for the full year was $17.1 million in 2022, compared to $23.2 million in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported full year 2023 results: revenue at least $22.0 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: at least $22.0 million
  - Guidance: initiated
  - Result: guidance update
  source text: For the full year 2023, the Company expects commercial revenue of at least $22.0 million, including the placement of at least 15 new systems.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.